Hypoglycaemia in diabetes — branching viva

Opening framework

My framework has three layers. First, the recognition — a confused, drowsy, or seizing child with type 1 diabetes is hypoglycaemic until proven otherwise, and I treat on suspicion without waiting for a laboratory value. Second, the physiology — the three-tier counter-regulatory defence (falling insulin, rising glucagon, rising adrenaline) fails in order in type 1 diabetes, and repeated events attenuate the adrenaline warning through hypoglycaemia-associated autonomic failure, which is the engine of recurrent severe and silent events. Third, the management — the rule of 15 for a conscious child and glucagon or intravenous dextrose for a severe event, followed by structured prevention through continuous glucose monitoring, hybrid closed-loop delivery, and two-to-three-week hypoglycaemia avoidance where awareness is impaired. [1] [2]

The emergency management and severity classification

For this six-year-old, the airway comes first: recovery position, oxygen if needed, and treatment without delay. The sensor reads 1.5 mmol/L, confirming a Level 2 biochemical event, but the functional state — a seizure and post-ictal drowsiness — makes this a Level 3 severe event, because severity is defined by the need for assistance regardless of the glucose value. His mother's intranasal glucagon was the correct community rescue and is supported by meta-analytic evidence of equivalence to the injectable form; if he does not wake within ten to fifteen minutes, intravenous dextrose at 0.2 to 0.3 grams per kilogram is the next step. Once awake, I follow with oral complex carbohydrate and protein, because the glucagon effect is transient. [1] [11]

Why the counter-regulation failed and the event was silent

In type 1 diabetes the first tier is lost outright, because the pump delivers insulin regardless of the glucose, with no endogenous insulin to switch off. The glucagon response is blunted by the loss of the intra-islet insulin signal. The adrenaline response, the third tier, is attenuated by any recent hypoglycaemia through HAAF, which lowers the symptom threshold and can silence the autonomic warning altogether. The nocturnal event was silent for two reasons: the autonomic response is physiologically blunted overnight, and his impaired awareness — likely from prior asymptomatic events — removed the tremor and sweating that would have woken him, leaving the seizure as the first symptom. [2] [3]

The rule of 15 and when glucagon or dextrose is indicated

For a conscious child who can swallow, the rule of 15 is the cornerstone: 15 grams of fast-acting carbohydrate — glucose tablets, gel, or 100 to 150 millilitres of juice — wait 15 minutes, recheck, and repeat up to three times before adding complex carbohydrate and protein. Glucose is preferred because it needs no first-pass metabolic step, and fat-containing foods are avoided because fat delays absorption. Glucagon or intravenous dextrose is indicated the moment the child cannot swallow safely or is unconscious or seizing — this boy crossed that line at the seizure, which is why intranasal glucagon was correct. [1]

The structured prevention plan

The download first: continuous glucose monitoring will reveal the nocturnal time below range and the variability driving both highs and lows. I would run two to three weeks of strict hypoglycaemia avoidance to restore the adrenaline warning, tune the hybrid closed-loop algorithm, rehearse the glucagon plan with school, and adjust the insulin — reduce rather than omit after events, fix any low overnight basal, and avoid stacked boluses. The DCCT taught us that intensive therapy prevents microvascular disease at the price of hypoglycaemia; modern technology and registry data show we can now reconcile the two. [4] [5]

Branch — impaired awareness and recurrent severe events

For the eight-year-old with three severe events in six months and lost warning, the diagnosis is impaired awareness, which affects around one in four children and is the strongest predictor of the next severe event. The mechanism is HAAF: each event attenuates the adrenaline response and lowers the symptom threshold below the neuroglycopenic threshold, so the warning disappears. The first intervention is two to three weeks of strict hypoglycaemia avoidance, which restores the warning before any technology is added, then hybrid closed-loop delivery to provide the automated defence his lost first tier cannot. [8] [2]

Branch — dead-in-bed and the equity of technology funding

The dead-in-bed syndrome is the catastrophic end of nocturnal hypoglycaemia: an unexpected overnight death in a young person with type 1 diabetes, linked to profound nocturnal hypoglycaemia and QT prolongation. It is rare, but it is the reason nocturnal hypoglycaemia is never dismissed as trivial and the reason continuous glucose monitoring with predictive low-glucose suspend matters. The equity point closes the viva: in Australia the NDSS funds continuous glucose monitoring for all children and young people under 21 with type 1 diabetes, and in New Zealand Pharmac funds it for children, which removes the cost barrier — but access still depends on prescription and family capacity to use the technology, so the equity work is not finished by funding alone. [10] [1]